As filed with the Securities and Exchange Commission on March 13, 2009
Registration No. 333-132740
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Panacos Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 11-3238476 | |
| (State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification Number) | |
| 134 Coolidge Avenue Watertown, Massachusetts |
02472 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
| Copies to: | ||
| Alan W. Dunton, M.D. President and Chief Executive Officer |
Megan N. Gates, Esq. | |
| Panacos Pharmaceuticals, Inc. | Mintz, Levin, Ferris, Glovsky & Popeo, P.C. | |
| 134 Coolidge Avenue | One Financial Center | |
| Watertown, Massachusetts 02472 | Boston, MA 02111 | |
| (617) 926-1551 | (617) 542-6000 | |
| (Name, address, including zip code, and telephone number, including area code, of agent for service) |
||
Not Applicable
(Approximate date of commencement of proposed sale to the public)
DEREGISTRATION OF UNSOLD SECURITIES
On March 27, 2006, Panacos Pharmaceuticals, Inc., formerly known as V.I. Technologies, Inc. (the “Company”), filed a Registration Statement on Form S-3 (File No. 333-132740) (the “Registration Statement”), to register up to $100,000,000 of shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) and warrants. This offering has been terminated because the Company intends to deregister its Common Stock under the Securities Exchange Act of 1934, as amended. Consequently, in accordance with an undertaking made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities that remain unsold at the termination of the offering, the Company hereby removes from registration the securities of the Company that are registered but unsold under the Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to its Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts on March 13, 2009.
| PANACOS PHARMACEUTICALS, INC. |
| /s/ Alan W. Dunton, M.D. |
| Alan W. Dunton, M.D. President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature |
Title |
Date | ||
| /s/ Alan W. Dunton, M.D. Alan W. Dunton, M.D. |
President and Chief Executive Officer and Director | March 13, 2009 | ||
| /s/ Robert B. Pelletier, CPA, MBA Robert B. Pelletier, CPA, MBA |
Vice President of Finance and Principal Accounting Officer | March 13, 2009 | ||
| /s/ Laurent Fischer, M.D. Laurent Fischer, M.D. |
Director | March 13, 2009 | ||
| /s/ Jeremy Hayward-Surry Jeremy Hayward-Surry |
Director | March 13, 2009 | ||